Alnylam (ALNY -0.7%) announces positive results from a pre-clinical ex vivo study, which takes place outside the organism, that could lead to the development of improved cellular vaccines for cancer and chronic viral infections. Alnylam's focus is RNA interference (RNAi), or the study of how genes are turned on and off in cells. (PR)
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Fri, 9:16AM)
at Nasdaq.com (Jan 23, 2015)
at Benzinga.com (Jan 12, 2015)
at CNBC.com (Jan 12, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs